Effects of GBT1118, a voxelotor analog, on bone disease in sickle cell disease mice

Area of Science:

• Biomedical Science
• Hematology
• Orthopedics

Background:

• Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal hemoglobin, leading to red blood cell sickling.
• SCD causes vaso-occlusion and chronic hemolysis, contributing to various complications, including bone loss and fragility.
• Current treatments for SCD primarily focus on managing symptoms and preventing complications, with limited options for addressing bone disease directly.

Purpose of the Study:

• To evaluate the efficacy of GBT1118, a novel sickle hemoglobin polymerization inhibitor, in ameliorating bone loss in a humanized mouse model of SCD.
• To investigate the impact of GBT1118 on bone microarchitecture, mineral density, and gene expression related to bone metabolism and hypoxia in SCD mice.

Main Methods:

• Humanized SCD mice and healthy controls were administered either vehicle or GBT1118 for two months.
• Bone parameters were assessed using micro-computed tomography (micro-CT) and bone histomorphometry.
• Gene expression analysis was performed on bone tissue to identify alterations in bone and hypoxia-related genes.

Main Results:

• GBT1118 significantly improved femur metaphyseal trabecular thickness and tissue mineral density in female SCD mice.
• In male SCD mice, GBT1118 increased bone volume fraction and tissue mineral density, partially rescuing deficits.
• GBT1118 treatment partially restored decreased mineralized trabeculae and normalized bone formation and resorption parameters in both male and female SCD mice.

Conclusions:

• GBT1118 demonstrates potential as a therapeutic agent for improving bone health in sickle cell disease.
• The study suggests that inhibiting sickle hemoglobin polymerization can counteract bone loss associated with SCD.
• Further research is warranted to explore the long-term effects and clinical applicability of GBT1118 in managing SCD-related bone disease.